- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 818261, 13 pages
Terpinen-4-ol Induces Apoptosis in Human Nonsmall Cell Lung Cancer In Vitro and In Vivo
1Department of Dermatology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan
2Department of Child Care, College of Humanities and Social Sciences, Southern Taiwan University, Tainan 71005, Taiwan
3Institute of Biomedical Sciences, College of Life Science, National Chung Hsing University, Taichung 40227, Taiwan
4Agricultural Research Institute, Council of Agriculture Executive, Yuan 10014, Taiwan
5Department of Internal Medicine, Division of Chest Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan
6Department of Medical Education and Research, Taichung-Veterans General Hospital, Taichung 40705, Taiwan
7Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan
Received 18 February 2011; Accepted 18 April 2011
Copyright © 2012 Chieh-Shan Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Terpinen-4-ol, a monoterpene component of the essential oils of several aromatic plants, exhibits antitumor effects. In this study, the antitumor effects of terpinen-4-ol and the cellular and molecular mechanisms responsible for it were evaluated and studied, respectively on human nonsmall cell lung cancer (NSCLC) cells. Our results indicated that terpinen-4-ol elicited a dose-dependent cytotoxic effect, as determined by MTT assay. Increased sub-G1 population and annexin-V binding, activation of caspases 9 and 3, cleavage of poly(ADPribose) polymerase (PARP), and a decrease of mitochondrial membrane potential (MMP) indicated involvement of the mitochondrial apoptotic pathway in terpinen-4-ol-treated A549 and CL1-0 cells. Elevation of the Bax/Bcl-2 ratio and a decrease in IAP family proteins XIAP and survivin were also observed following terpinen-4-ol treatment. Notably, terpinen-4-ol was able to increase p53 levels in A549 and CL1-0 cells. Diminution of p53 by RNA interference induced necrosis instead of apoptosis in A549 cells following terpinen-4-ol treatment, indicating that terpinen-4-ol-elicited apoptosis is p53-dependent. Moreover, intratumoral administration of terpinen-4-ol significantly suppressed the growth of s.c. A549 xenografts by inducing apoptosis, as confirmed by TUNEL assay. Collectively, these data provide insight into the molecular mechanisms underlying terpinen-4-ol-induced apoptosis in NSCLC cells, rendering this compound a potential anticancer drug for NSCLC.
Lung cancer is the leading cause of cancer-related deaths worldwide. Among lung cancers, nonsmall cell lung carcinomas (NSCLC) account for approximately 80% of lung cancer cases . Despite improvements in survival through early detection and treatment, rapid disease recurrence and progression still plague some patients . Thus, the search for new therapeutic approaches is still important and urgently needed in clinical oncology.
Monoterpenes are major plant-derived secondary metabolites; they consist of two isoprene units, are found in essential oils, and are associated with plant defense [3, 4]. In addition, numerous monoterpenes have been proposed to exert potent antitumor action, and some have shown promising results in the prevention and treatment of a variety of cancers in tumor model systems [5, 6]. Notably, two naturally occurring monoterpenes, perillyl alcohol (POH) and limonene (LIM), are currently undergoing clinical trials to evaluate their therapeutic effect [7, 8].
Terpinen-4-ol, a naturally occurring monoterpene found in the essential oils of many aromatic plants including Melaleuca alternifolia (tea tree oil), Hajeb Layoun arboreta (Tunisia) and Alpinia zerumbet, has been shown to have antiviral, antibacterial, antifungal, and insecticidal effects as well as antioxidant and anti-inflammatory activities [9–13]. Recent reports have indicated that terpinen-4-ol exerts its antitumor effects by triggering caspase-dependent apoptosis in human melanoma cells or by inducing necrotic cell death and cell-cycle arrest in mouse mesothelioma and melanoma cell lines without affecting normal cells [14, 15].
Although these findings demonstrate the anticancer activity of terpinen-4-ol, the underlying molecular mechanisms of the antitumor activity of terpinen-4-ol remain unclear. In addition, there is no report on the antitumor effects of terpinen-4-ol against human nonsmall cell lung cancer cells. Therefore, in this study, the anticancer effects of terpinen-4-ol were evaluated on two NSCLC cell lines, namely, A549 and CL1-0 human lung adenocarcinoma cells. The possible molecular mechanisms responsible for its anticancer activity were also investigated. Our results indicated that terpinen-4-ol induced apoptosis through a mitochondria-mediated pathway in NSCLC cells and that the apoptosis elicited by terpinen-4-ol was p53 dependent. Furthermore, treatment of s.c xenografts derived from A549 cells with intratumor injections of terpinen-4-ol significantly inhibited tumor growth compared with the control group.
2. Materials and Methods
2.1. Cell Culture and Reagents
The A549 human lung adenocarcinoma and CL1-0 lung adenocarcinoma cell lines were cultured in Dulbecco′s modified eagle medium supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic antimycotic. Cultures were maintained in a humidified incubator with 5% CO2 at 37°C. The A549/p53-shRNA clone 14 cells were established in culture as described by Chang et al. . Terpinen-4-ol (Sigma-Aldrich, St. Louis, MO) was 97% pure. A 0.2% stock solution of terpinen-4-ol was prepared and was subsequently diluted to 0.02%–0.1% in warm supplemented media .
2.2. Cytotoxicity Assay
The cytotoxic effects of terpinen-4-ol on A549 and CL1-0 cells were measured with the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium (MTT) assay (Sigma-Aldrich, St. Louis, Mo, USA). The A549 and CL1-0 cells were seeded onto 24-well plates for 24 hours. Various concentrations of terpinen-4-ol were added to the cells. After incubation for 24 hours, the medium was removed, and 200 μL of 1 × MTT solution was added to each well for 4 hours. The spectrophotometric absorbance of each well was analyzed by a microplate reader (TECAN) at 540 nm. For analysis of the cytotoxic efficiency, we calculated IC50 values with dose-dependent curves by linear interpolation.
2.3. Western Blot Analysis
Whole-cell protein was lysed with 2% SDS (10 mM EDTA, 50 mM Tris base, 10% SDS, pH 8.0) and boiled at 100°C for 10 minutes. Protein concentrations were measured using the BCA protein assay. Equal amounts of protein were loaded on 10%–15% SDS-PAGE gels, transferred to PVDF membranes and blocked with 5% nonfat milk in TBST buffer (20 mM Tris-HCl, 120 mM NaCl, 0.1% Tween 20) for 1 hour. Membranes were incubated with various primary antibodies against Cyclin B1, Cdc2, Cdc25c, Bcl-2, Bax, caspase-3, caspase-9, and PARP at 4°C overnight. After washing, the blots were incubated with HRP-labeled secondary antibodies for 2 hours. The signals of the blots were then developed using the enhanced chemiluminescence (ECL) system and analyzed with the LAS3000 system (Fujifilm, Tokyo, Japan).
2.4. Mitochondria/Cytosol Fractionation
A mitochondria/cytosol fractionation kit (Biovision) was used for isolation of the mitochondrial fraction from the cytosolic fraction of mammalian cells. Cells were harvested by trypsinization, washed twice with PBS and resuspended in 500 μL of cytosol extraction buffer mix on ice for 10 minutes. Cells were homogenized with a Dounce tissue grinder (Biovision) on ice for 30–50 passes and centrifuged at 3000 rpm for 10 minutes at 4°C. The supernatants were collected and centrifuged again at 13000 rpm for 30 minutes at 4°C.
2.5. Cell Cycle Analysis and Sub-G1 Measurement
3 × 105 cells were plated on 6 cm dishes for 24 hours. The cells were then treated with different concentrations of terpinen-4-ol for different periods of time, followed by collecting the cells by centrifugation. The pellets were mixed with 75% ethanol at −20°C overnight. The cells were then centrifuged and resuspended in 500 μL of PI staining solution (2 mg/mL RNase, 1 mg/mL PI, 5% Triton X-100) for 1 hour at 37°C in the dark. The cells were next analyzed by FACS Calibur flow cytometry (BD Biosciences). The distribution and percentages of cells in the sub-G1, G0/G1, S, and G2/M phases of the cell cycle were further analyzed with WinMDI software (version 2.9, Joseph Trotter).
2.6. Annexin V Assay
The BioVision annexin V-FITC apoptosis detection kit was used for the apoptosis assay (BioVision). A549 and CL1-0 cells were seeded onto 6 cm dishes for 24 hours and then exposed to different doses of terpinen-4-ol for 6 hours. Cells were harvested by trypsinization, washed twice with PBS, and resuspended in 500 μL of binding buffer. Cell suspensions were then incubated with 5 μL of annexin V-FITC and 5 μL of propidium iodide (PI) for 10 minutes at room temperature in the dark. The cells were evaluated immediately by flow cytometry.
2.7. Mitochondrial Membrane Potential Assay
Mitochondria-specific cationic dye JC-1 (Invitrogen, Carlsbad, Calf, USA), which undergoes potential-dependent accumulation in the mitochondria, was used. When the membrane potential is below 120 mV, JC-1 is monomeric and emits green light (540 nm) following excitation with blue light (490 nm). At membrane potentials higher than 120 mV, JC-1 monomer aggregates and emits red light (590 nm) following excitation with green light (540 nm). For the assay, cells were seeded onto 96-well plates and treated with various concentrations of terpinen-4-ol for 24 hours, followed by staining with 25 μM JC-1 for 30 minutes at 37°C. Fluorescence was monitored with a fluorescence plate reader at wavelengths of 490 nm (excitation)/540 nm (emission) and 540 nm (excitation)/590 nm (emission). Changes in the mitochondrial membrane potential were indicated by changes in the ratio of intensities between the measurements at test wavelengths of 590 nm (red) and 540 nm (green).
2.8. In Vivo Antitumor Activity
In total, 1 × 107 A549 cells were s.c. injected into the right flank of 16 week old female BALB/c nu/nu mice. Tumor-bearing mice were subdivided into groups of five mice. Therapy was initiated 10 days after tumor inoculation when the mean tumor volume was 50 mm3. A stock solution of terpinen-4-ol was made by dissolving 11 μL in 5.5 mL PBS with vigorous vortexing. This 0.2% solution was further diluted in PBS. Tween 80 (final concentration 0.001% v/v) was included to facilitate oil solubility . Mice were intravenously infused daily with 100 μL of terpinen-4-ol at the indicated doses (0.06% and 0.1%). Control mice were intravenously infused daily with 100 μL of PBS containing 0.001% Tween 80. Tumor volumes were calculated as length × width × thickness × 0.5 and expressed in mm3.
2.9. TUNEL Assay
Apoptotic cell death in paraffin-embedded tumor tissue sections was examined using the TdT-FragEL DNA fragmentation detection kit (Calbiochem, San Diego, Calf, USA) according to the manufacturer's instructions. Apoptotic cells were identified as dark brown nuclei under a light microscope. The number of apoptotic cells was counted in five randomly selected high-power fields in a blinded manner.
2.10. Statistical Analysis
Results are expressed as mean ± SD. Statistical comparisons between two groups of data were made using an unpaired two-tailed Student's -test, and values <.05 were considered significant.
3.1. Cytotoxic Effects of Terpinen-4-ol in A549 and CL1-0 Cells
To determine the cytotoxic effect of terpinen-4-ol on cell, A549 and CL1-0 cells were treated with 0.02% to 0.1% terpinen-4-ol for 24 hours, and cell viability was determined using the MTT assay. As shown in Figure 1(a), the viability of A549 and CL1-0 cells was markedly reduced by terpinen-4-ol in a concentration-dependent manner. The results were expressed as a percentage relative to the control group. At 24 hours, the estimated IC50 values were 0.052% in A549 cells and 0.046% in CL1-0 cells, respectively. In addition, the morphological changes in terpinen-4-ol-treated cells at 24 hours were also examined using a phase contrast microscope, as illustrated in Figure 1(b). At concentrations up to 0.06%, cell proliferation was inhibited, but the cells remained mostly alive. At concentrations of 0.08% and higher, the compound induced cell death with marked morphologic changes such as shrinkage, rounding, and floating of the cells. These morphological changes suggested that terpinen-4-ol might induce apoptotic cell death in human NSCLC cells.
3.2. Terpinen-4-ol Induces Apoptosis in A549 and CL1-0 Cells
To determine whether terpinen-4-ol causes cell growth inhibition by inducing cell-cycle arrest, A549 and CL1-0 cells were subjected to flow cytometric analysis. Both A549 and CL1-0 cells were exposed to a series of concentrations of terpinen-4-ol for 24 hours. Figure 2(a) shows that when exposed to 0.06% terpinen-4-ol for 24 hours, a high number of cells were arrested in the G2/M phase. Additionally, the sub-G1 population, which is an indication of cell death, increased significantly in the presence of 0.08% and 0.1% terpinen-4-ol. To clarify the type of cell death elicited by terpinen-4-ol, A549 and CL1-0 cells were treated with various concentrations of terpinen-4-ol for 24 hours and subjected to flow cytometry analysis after staining with annexin V-FITC and propidium iodide (PI). As shown in Figure 2(b), the percentages of early apoptotic death (annexin V+/PI− and lower right quadrant) and late apoptotic and necrotic death (annexin V+/PI+ and upper right quadrant) increased in a dose-dependent manner in A549 cells. The percentage of early apoptotic death in CL1-0 cells rose at lower doses of terpinen-4-ol but fell slightly at higher doses, whereas the percentages of late apoptotic and necrotic death in CL1-0 cells still increased in a dose-dependent manner. The former phenomenon seen in CL1-0 cells should be attributed to its higher sensitivity to terpinen-4-ol, thereby causing DNA fragmentation to occur earlier. Taken together, these results suggest that terpinen-4-ol induces apoptosis in A549 and CL1-0 cells.
3.3. Terpinen-4-ol Induces Caspase-Dependent Cell Death in A549 and CL1-0 Cells
Apoptosis can be elicited by chemotherapeutic agents, and the signal transduction can be generally divided into the intrinsic, mitochondria-mediated, and extrinsic pathways . These pathways converge at several downstream points, including caspase-3, and/or caspase-7. Activated caspase-3 and/or caspase-7 then cleave poly(ADP-ribose)polymerase (PARP), which eventually leads to apoptosis. Thus, to clarify the type of apoptotic pathway induced by terpinen-4-ol, the cleaved forms of caspase-8, caspase-9, caspase-3 and PARP were determined by Western blot analysis. As illustrated in Figure 3(a), the cleaved/activated forms of caspase-9, caspase-3, and PARP, but not caspase-8, were induced at higher concentrations of terpinen-4-ol in A549 and CL1-0 cells. Activation of caspase-9 and caspase-3 by terpinen-4-ol suggests that the mitochondrial pathway is involved. Therefore, we used various caspase inhibitors to investigate one step further. As illustrated in Figure 3(b), the specific caspase 8 inhibitor Z-IETD was completely ineffective at increasing cell viability, thereby excluding the possibility of involvement of the extrinsic pathway in terpinen-4-ol-induced apoptosis. However, caspase-3 inhibitor Z-DEVD and the caspase-9 inhibitor Z-LEHD were effective in rescuing both A549 and CL1-0 cells, indicating that the intrinsic, mitochondria-mediated apoptotic pathway was the mechanism executing terpinen-4-ol-induced apoptosis.
3.4. Terpinen-4-ol Induced Loss of Mitochondrial Membrane Potential and Cytochrome C Release
To confirm that the intrinsic, mitochondria-mediated apoptotic pathway was involved, we further measured the mitochondrial membrane potential in terpinen-4-ol-treated A549 and CL1-0 cells. Loss of mitochondrial membrane potential is an indicator of mitochondrial damage during apoptosis. We used the fluorescent cationic dye JC-1 to examine the effect of terpinen-4-ol on membrane potential . JC-1 is a mitochondria-specific probe that aggregates in normally polarized mitochondria and emits red fluorescence. In apoptotic depolarized cells, where the mitochondrial membrane potential is reduced, JC-1 is diffused throughout the cells and assumes a monomeric form, which emits green fluorescence. A concentration-dependent decrease in red fluorescence was observed in both A549 and CL1-0 cells, suggesting that terpinen-4-ol treatment led to a reduction in (Figure 4(a)). A loss of can lead to cytochrome c release from the mitochondria into the cytosol, an important event for apoptosis induction . Thus, the cytosolic fractions of A549 and CL1-0 cells treated with various doses of terpinen-4-ol were prepared and analyzed for cytochrome c release by Western blotting. As shown in Figure 4(b), cytochrome c expression in the cytosolic fractions was observed in both A549 and CL1-0 cells treated with higher concentrations of terpinen-4-ol. Taken together, we verified that the mitochondrial pathway was responsible for the terpinen-4-ol-induced apoptosis.
3.5. Terpinen-4-ol Reduced Bcl-2, Bcl-xl and Iaps Protein Expression in A549 and CL1-0 Cells
Having shown mitochondrial involvement in terpinen-4-ol-induced apoptosis, we next focused on the Bcl-2 family members, which are known regulators of cytochrome c release from mitochondria during apoptosis. We examined the protein expression of a proapoptotic member, Bax, which triggers cytochrome c release, and an antiapoptotic member, Bcl-2, which inhibits cytochrome c release . Higher doses of terpinen-4-ol treatment on A549 and CL1-0 cells for 24 hours resulted in decreased Bcl-2 protein levels and increased Bax protein expression (Figure 5). In addition to the Bcl-2 family, the IAP family proteins also regulate caspase activity, thus affecting apoptosis . Therefore, the expression of two IAP family proteins, survivin and XIAP, were determined. As shown in Figure 5, XIAP and survivin protein expression were reduced at higher doses of terpinen-4-ol.
3.6. Terpinen-4-ol-Induced Apoptosis Is p53 Dependent
p53 is known to play important roles in apoptosis [22, 23]; therefore, we wanted to determine whether p53 plays an important role in terpinen-4-ol-induced apoptosis. Our results showed that tepinen-4-ol increased p53 protein expression in both A549 and CL1-0 cells. To further clarify the role of p53 protein, p53 was diminished by shRNA in A549 cells. Although cell viability, as determined by the MTT assay following terpinen-4-ol treatment, was significantly lower in p53-diminished A549 cells compared with wild-type A549 cells (Figure 6(a)), we surprisingly found that terpinen-4-ol induced mostly necrosis in these cells based on annexin V flow cytometric analyses (Figure 6(c)). The necrotic cell death was characterized as PI+/annexin V-by flow cytometry. Further analysis demonstrated that terpinen-4-ol failed to activate caspase 3 and PARP in p53-deficient A549 cells (Figure 6(b)), which confirmed that necrotic cell death was occurring. These results suggest that p53 is a prerequisite to terpinen-4-ol-induced apoptosis.
3.7. Terpinen-4-ol Inhibits A549 Tumor Growth in a S.C. Tumor Model
The prominent inhibitory effect of terpinen-4-ol on NSCLC cell proliferation in vitro suggested that it might suppress tumor growth in vivo. To verify this hypothesis, female BALB/c nu/nu mice were s.c. inoculated with A549 cells, followed by the indicated doses of terpinen-4-ol therapy starting on day 10 after tumor inoculation. As shown in Figure 7(a), terpinen-4-ol dose-dependently reduced tumor volume in BALB/c nu/nu mice. To further confirm the ability of terpinen-4-ol to elicit apoptosis in vivo, in situ TUNEL staining was carried out on tissue sections of tumors excised on day 28 from A549 cell-implanted mice treated with various doses of terpinen-4-ol. As illustrated in Figure 7(b), 0.1% terpinen-4-ol treatment caused a significantly higher percentage of TUNEL-positive apoptotic cells compared with vehicle treatment. These results indicated that terpinen-4-ol also inhibits the growth of nonsmall lung cancer cells and is a potent apoptosis-inducing agent in vivo.
Terpinen-4-ol, a major component of essential oil from several aromatic plants, is used as an anti-inflammatory and antioxidant agent [9–13]. This compound also exhibits antiproliferative and antitumor effects in the murine AE17 mesothelioma and B16 melanoma tumor cell lines and human melanoma M14 WT cells, as well as their drug-resistant counterparts, M14 adriamicin-resistant cells [14, 15]. Our results demonstrate for the first time that terpinen-4-ol induces apoptosis in human lung cancer cells in vitro and in vivo. Elevation of the Bax/Bcl-2 ratio and a decrease in IAP family proteins XIAP and survivin were observed following terpinen-4-ol treatment. Notably, our results also indicated that terpinen-4-ol-induced apoptosis is p53 dependent.
Apoptosis and necrosis are two typical types of cell death . Apoptosis is characterized by several biochemical criteria such as changes in mitochondrial membrane permeability, caspase signaling activation, internucleosomal DNA cleavage, and the release of intermembrane mitochondrial proteins . In contrast, necrosis is characterized mostly in negative terms by the absence of apoptosis parameters, such as caspase activation . Recently, accumulating evidence has indicated that the dysregulation of apoptosis contributes to carcinogenesis [26, 27]. Therefore, it has been suggested that susceptibility to chemotherapeutic agents is dependent on the ability of tumor cells to respond to apoptosis. Terpinen-4-ol has been shown to induce caspase-dependent apoptosis in human melanoma cells. However, terpinen-4-ol has also been shown to induce necrosis in AE17 murine mesothelioma and B16 murine melanoma cells . The difference in type of cell death elicited by terpinen-4-ol might be explained by species or cell type differences. In our present study, the presence of early apoptotic cells (annexin V+/PI−), activated forms of caspase-9 and caspase-3, and PARP cleavage indicated that apoptosis, rather than necrosis, was involved in terpinen-4-ol-induced A549 and CL1-0 cell death (Figures 2 and 3). Furthermore, the decrease in mitochondrial membrane potential and increase in cytochrome c release into the cytosol confirmed involvement of the mitochondrial pathway of apoptosis upon the treatment with terpinen-4-ol.
Bcl-2 family proteins including proteins that suppress apoptosis, such as Bcl-2, Bcl-XL, and Mcl-1, and proteins that promote apoptosis, such as Bad, Bax, and Bid, have been reported to play a central role in regulating cytochrome c release from mitochondria . Thus, the balance between the expression levels of antiapoptotic and proapoptotic Bcl-2 family proteins is critical for the fate of a cell. Moreover, IAPs have also been reported to inhibit apoptosis by functioning as inhibitors of activated effector caspases, such as caspase-3 and caspase-7. IAPs are also able to inhibit the cytochrome c-induced activation of caspase-9 . Our data revealed that the protein expression of antiapoptotic Bcl-2, XIAP, and survivin were reduced and that of proapoptotic Bax was elevated 24 hours after terpinen-4-ol treatment (Figure 4). These results revealed the molecular events occurring during terpinen-4-ol-induced mitochondria-mediated apoptosis.
The p53 tumor-suppressor protein protects against cancer by regulating the cellular response to DNA damage, apoptosis, and oncogene activation [22, 23]. Diminution of p53 expression by shRNA did not decrease the susceptibility of A549 cells to terpinen-4-ol-induced cytotoxicity, but a significant reduction in the proportion of apoptosis was observed in p53-diminished A549 cells. Instead of apoptosis, necrosis manifested as a result of p53 diminution in A549 cells (Figure 6). This finding suggests that p53 is essential to terpinen-4-ol-induced apoptosis in human NSCLC cancer cells and that necrosis is responsible for the cytotoxic effect of terpinen-4-ol in p53-null NSCLC cancer cells. Therefore, the presence of functional p53 acts as the key factor in switching necrosis to apoptosis in human NSCLC. This is similar to a previous study from Lim et al. in which ursodeoxycholic acid was able to switch oxaliplatin-induced necrosis to apoptosis by activating the p53-caspase 8 pathway in HepG2 hepatocellular carcinoma . Our results do not exclude the possibility of a failure to induce apoptosis in cancer cells, where p53 is mutated and loses its transactivation ability, because p53 mutations are varied. In other words, terpinen-4-ol is most effective against cancers with functional p53.
Cell-cycle arrest is a common cause of cell growth inhibition . Previous studies have indicated that treatment with terpinen-4-ol induces antiproliferative effects by causing G1 phase arrest in AE17 murine mesothelioma and B16 murine melanoma cells . However, in the present study, we observed that the exposure of A549 and CL1-0 cells to terpinen-4-ol caused G2/M phase arrest (Figure 2(a)). Again, the difference in type of cell-cycle arrest elicited by terpinen-4-ol might be due to species or cell-type differences. Cell-cycle progression is controlled by the activation of a highly conserved family of protein kinases, the cyclin-dependent kinases (Cdks), and the expression of their cyclin partners, whereas inhibitors of Cdks, including p21 and p27, inhibit Cdk activity by binding to Cdk-cyclin complexes [30, 31]. Assembly of the cyclin B1/Cdc2 protein complex is essential for G2-phase progression and G2/M transition . In addition Cdc25c phosphatase is a key activator of Cdc2/cyclin B at the G2/M transition. Cdc25c functions by dephosphorylating, and thereby activating, Cdc2 . Although it is not fully understood how DNA damage causes cells to undergo apoptosis at the G2/M checkpoint, our results indicate that the expression of cyclin B1 and cdc25c decrease when cells are treated with terpinen-4-ol as compared to the untreated control (see in supplementary materials in doi: 10.1155/2012/818261). However, the expression of Cdc2 and cdk inhibitors p21 and p27 was unaffected by terpinen-4-ol (see in supplementary materials in doi: 10.1155/2012/818261). One of the important mechanisms through which p53 can regulate the cell cycle is to induce cdk inhibitor p21, which can induce G2/M or G1 arrest . Because p21 and p27 protein expression remained unchanged following terpinen-4-ol treatment, it is plausible that terpinen-4-ol induces G2/M arrest via a p53 independent mechanism, and that decreases in the expression of cyclin B1 and Cdc25c contribute mainly to the G2/M arrest seen in terpinen-4-ol-treated lung cancer cells.
In conclusion, we demonstrated that caspase-dependent mitochondrial dysfunction is the mechanism of terpinen-4-ol-induced apoptosis in nonsmall lung cancer cells. Downregulation of Bcl-2, XIAP and survivin suggests that terpinen-4-ol increases the susceptibility of NSCLC cells to apoptosis induction. Notably, the ability of terpinen-4-ol to induce apoptosis in NSCLC cells is p53-dependent. Finally, our data also showed that the growth of s.c. xenograft tumors was remarkably inhibited by intratumoral injection of terpinen-4-ol, indicating that the agent also has potential for clinical anticancer activity. However, further work is needed to develop a suitable formulation for either systemic administration or convection-enhanced delivery of the compound to patients.
Conflict of Interests
The authors declare that they have no conflicts of interests.
This study was supported by grants from the Kaohsiung Veterans General Hospital (VGHKS 99-011) and in part by the Ministry of Education, Taiwan, under the ATU plan. C.-S. Wu and Y.-J. Chen contributed equally to this work.
- D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Estimating the world cancer burden: globocan 2000,” International Journal of Cancer, vol. 94, no. 2, pp. 153–156, 2001.
- P. J. Souquet, F. Chauvin, J. P. Boissel et al., “Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis,” Lancet, vol. 342, no. 8862, pp. 19–21, 1993.
- J. Gershenzon and N. Dudareva, “The function of terpene natural products in the natural world,” Nature Chemical Biology, vol. 3, no. 7, pp. 408–414, 2007.
- K. H. Wagner and I. Elmadfa, “Biological relevance of terpenoids: overview focusing on mono-, di- and tetraterpenes,” Annals of Nutrition and Metabolism, vol. 47, no. 3-4, pp. 95–106, 2003.
- S. S. Clark, S. M. Perman, M. B. Sahin, G. J. Jenkins, and J. A. Elegbede, “Antileukemia activity of perillyl alcohol (POH): uncoupling apoptosis from G0/G1 arrest suggests that the primary effect of POH on Bcr/Abl-transformed cells is to induce growth arrest,” Leukemia, vol. 16, no. 2, pp. 213–222, 2002.
- L. Yeruva, K. J. Pierre, A. Elegbede, R. C. Wang, and S. W. Carper, “Perillyl alcohol and perillic acid induced cell cycle arrest and apoptosis in non small cell lung cancer cells,” Cancer Letters, vol. 257, no. 2, pp. 216–226, 2007.
- C. O. Da Fonseca, M. Masini, D. Futuro, R. Caetano, C. Rocha Gattass, and T. Quirico-Santos, “Anaplastic oligodendroglioma responding favorably to intranasal delivery of perillyl alcohol: a case report and literature review,” Surgical Neurology, vol. 66, no. 6, pp. 611–615, 2006.
- C. O. da Fonseca, G. Schwartsmann, J. Fischer et al., “Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas,” Surgical Neurology, vol. 70, no. 3, pp. 259–266, 2008.
- A. Astani, J. Reichling, and P. Schnitzler, “Comparative study on the antiviral activity of selected monoterpenes derived from essential oils,” Phytotherapy Research, vol. 24, no. 5, pp. 673–679, 2010.
- J. D. Cha, M. R. Jeong, S. I. Jeong et al., “Chemical composition and antimicrobial activity of the essential oil of Cryptomeria japonica,” Phytotherapy Research, vol. 21, no. 3, pp. 295–299, 2007.
- A. Barra, V. Coroneo, S. Dessi, P. Cabras, and A. Angioni, “Characterization of the volatile constituents in the essential oil of Pistacia lentiscus l. from different origins and its antifungal and antioxidant activity,” Journal of Agricultural and Food Chemistry, vol. 55, no. 17, pp. 7093–7098, 2007.
- D. E. Wedge, N. Tabanca, B. J. Sampson et al., “Antifungal and insecticidal activity of two juniperus essential oils,” Natural Product Communications, vol. 4, no. 1, pp. 123–127, 2009.
- B. Zúñiga, P. Guevara-Fefer, J. Herrera et al., “Chemical composition and anti-inflammatory activity of the volatile fractions from the bark of eight Mexican Bursera species,” Planta Medica, vol. 71, no. 9, pp. 825–828, 2005.
- S. J. Greay, D. J. Ireland, H. T. Kissick et al., “Induction of necrosis and cell cycle arrest in murine cancer cell lines by Melaleuca alternifolia (tea tree) oil and terpinen-4-ol,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 5, pp. 877–888, 2010.
- A. Calcabrini, A. Stringaro, L. Toccacieli et al., “Terpinen-4-ol, the main component of Melaleuca alternifolia (Tea Tree) oil Inhibits the in Vitro growth of human melanoma cells,” Journal of Investigative Dermatology, vol. 122, no. 2, pp. 349–360, 2004.
- G. C. Chang, C. T. R. Yu, C. H. Tsai et al., “An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells,” European Journal of Pharmacology, vol. 600, no. 1–3, pp. 37–44, 2008.
- F. Mondello, F. De Bernardis, A. Girolamo, A. Cassone, and G. Salvatore, “In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species,” BMC Infectious Diseases, vol. 6, article no. 158, 2006.
- A. H. Wyllie, J. F. R. Kerr, and A. R. Currie, “Cell death: the significance of apoptosis,” International Review of Cytology, vol. 68, pp. 251–306, 1980.
- P. Li, D. Nijhawan, I. Budihardjo et al., “Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade,” Cell, vol. 91, no. 4, pp. 479–489, 1997.
- J. K. Brunelle and A. Letai, “Control of mitochondrial apoptosis by the Bcl-2 family,” Journal of Cell Science, vol. 122, no. 4, pp. 437–441, 2009.
- Y. L. Yang and X. M. Li, “The IAP family: endogenous caspase inhibitors with multiple biological activities,” Cell Research, vol. 10, no. 3, pp. 169–177, 2000.
- M. B. Kastan, O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig, “Participation of p53 protein in the cellular response to DNA damage,” Cancer Research, vol. 51, no. 23, pp. 6304–6311, 1991.
- A. J. Levine, “p53, the cellular gatekeeper for growth and division,” Cell, vol. 88, no. 3, pp. 323–331, 1997.
- N. A. Thornberry and Y. Lazebnik, “Caspases: enemies within,” Science, vol. 281, no. 5381, pp. 1312–1316, 1998.
- C. Kitanaka and Y. Kuchino, “Caspase-independent programmed cell death with necrotic morphology,” Cell Death and Differentiation, vol. 6, no. 6, pp. 508–515, 1999.
- S. H. Kaufmann and G. J. Gores, “Apoptosis in cancer: cause and cure,” BioEssays, vol. 22, no. 11, pp. 1007–1017, 2000.
- G. T. Williams, “Programmed cell death: apoptosis and oncogenesis,” Cell, vol. 65, no. 7, pp. 1097–1098, 1991.
- S. C. Lim, J. E. Choi, H. S. Kang, and H. Si, “Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma,” International Journal of Cancer, vol. 126, no. 7, pp. 1582–1595, 2010.
- R. Leake, “The cell cycle and regulation of cancer cell growth,” Annals of the New York Academy of Sciences, vol. 784, pp. 252–262, 1996.
- Y. Xiong, G. J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach, “p21 is a universal inhibitor of cyclin kinases,” Nature, vol. 366, no. 6456, pp. 701–704, 1993.
- K. Polyak, J. Y. Kato, M. J. Solomon et al., “p27(Kip1), a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest,” Genes and Development, vol. 8, no. 1, pp. 9–22, 1994.
- C. Laronga, H. Y. Yang, C. Neal, and M. H. Lee, “Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression,” Journal of Biological Chemistry, vol. 275, no. 30, pp. 23106–23112, 2000.
- F. Liu, J. J. Stanton, Z. Wu, and H. Piwnica-Worms, “The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex,” Molecular and Cellular Biology, vol. 17, no. 2, pp. 571–583, 1997.
- M. Motwani, X. K. Li, G. K. Schwartz et al., “The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow,” Clinical Cancer Research, vol. 6, no. 4, pp. 1498–1507, 2000.